A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination with Durvalumab in Selected Advanced Solid Tumors
- Frentzas, Sophia (Primary Chief Investigator (PCI))
Project: Research